Hematolymphoid Neoplasm Gene Mutation Panel, NGS
The hematolymphoid neoplasm gene mutation panel identifies mutations commonly seen in hematolymphoid neoplasms. These are tumors that affect the blood, bone marrow, lymph nodes, spleen and other tissues. Hematological malignancies arise from cells of the bone marrow or the immune system. The majority of these neoplasms arise from either the granulocytic or lymphoid lineages and may arise at multiple points during the maturational sequence of these cells. From a clinical standpoint these cancers are segregated into acute disorders (e.g. acute myelogenous leukemias (AML), acute lymphoblastic leukemias (ALL), and aggressive forms of lymphoma) and chronic disorders (e.g. chronic myeloproliferative disorders (MPD), chronic lymphocytic leukemia (CLL), indolent lymphomas, etc.). Additionally, there are disorders which are considered ‘pre-malignant’ such as myelodysplastic syndromes (MDS), and oligoclonal lymphoid proliferations. Finally, there are disorders that are believed to arise from uncommon cell types such as dendritic cells, marrow fibroblasts, Langerhans cells and histiocytes.
Our understanding of the lineage, pathology, prognosis and therapy of these disorders has been greatly enhanced by evaluating their genetic features and identifying common mutations underlying their pathogenesis. Using next generation sequencing techniques, panels of mutations common to specific types of hematologic malignancy, may be performed to identify mutations that have diagnostic, prognostic and therapeutic implications. Although panels containing hundreds of mutations are available for clinical use, the NCCN and other groups advocate the use of smaller panels of < 50 mutations for specific disorders. # Panel Components Although individual panel components may vary based on the laboratory performing the testing the clinically useful mutations for the various types of disorders are:
AML: RUNX1, CBFB-MYH11, PML-RARA, NUP214, MECOM, NPM1, FLT3-ITD TKD, CEBPA, BCR-ABL
MDS: SF3B1, Del5q
MPD: BCR-ABL, JAK2, CALR, MPL, SETBP1, CSF3R # B-ALL: BCR-ABL, iAMP 21
T-ALL: NOTCH1, CDKN2A/B, PHF6, FBXW7 # CLL: NOTCH1, SF3B1, TP53, ATM
Follicular lymphomas: BCL2, BCL6, MYC # Diffuse lymphomas: ALK, DUSP22/IRF4
Other mutations that may be included in such panels include: ABL, KDM6A, ASXL1, KIT, ATRX, KRAS, BCOR, BCORL1, MLL, MPL, BRAF, MYD88, CALR, NOTCH1, CBL, NPM1, CBLB, NRAS, CBLC, PDGFRA, PHF6, CEBPA, PTEN, CSF3R, PTPN11, CUX1, RAD21, DNMT3A, RUNX1, ETV6/TEL, SETBP1, EZH2 SF3B1, FBXW7, SMC1A, FLT3, SMC3, SRSF2, GATA2, STAG2, GNAS, TET2, HRAS, TP53, IDH1, USAF1, IDH2, WT1, IKZF1, ZRSR2, JAK2
- To confirm a diagnosis of hematologic and lymphoid neoplasms
- For identifying mutations within genes known to be associated with increased risk for hematolymphoid cancer allowing for predictive testing of at-risk family members
- As an aid in the differential diagnosis of clinically similar hematologic neoplasms
- For the selection of therapy regimens, consideration of bone marrow or stem cell transplant, long-term cancer surveillance and prognosis, and counseling of the patients
Positive: At least one known pathogenic variant or mutation associated with hematolymphoid neoplasm should be detected. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants.
Negative for mutations or pathogenic variants analyzed
Whole blood, bone marrow aspirates (anticoagulated with either heparin or EDTA and, if possible, placed into tissue culture medium).
Stability
- Ambient: 3-5 days
- Refrigerated: 7 days
- Blood. 2017;130: 410-423. [PMID: 28600336]
- Blood Cells Mol Dis. 2018;69: 90-100. [PMID: 29079134]
- Arch Pathol Lab Med. 2017;141: 341-354. [PMID: 28055240]
- Methods Mol Biol. 2017;1633: 33-49. [PMID: 28735479]
- Leuk Lymphoma. 2016;57(1):76-80. [PMID: 26084204]
- Blood. 2011;118: 1723-35. [PMID: 21653328]